Testing for COVID-19 in patients with cancer
- PMID: 32368727
- PMCID: PMC7196399
- DOI: 10.1016/j.eclinm.2020.100374
Testing for COVID-19 in patients with cancer
Conflict of interest statement
VS reports Research funding/ Grant support for clinical trials: Roche/ Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo oncology, Medimmune, Altum, Dragonfly therapeutics, Takeda and, National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning point therapeutics, Boston Pharmaceuticals Travel: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte, Consultancy/ Advisory board: Helsinn, LOXO Oncology/ Eli Lilly, R-Pharma US, INCYTE, QED pharma, Medimmune, Novartis. Other: Medscape. Others report no conflict of interest.
References
-
- Rosenbaum L. The Untold Toll — The Pandemic's Effects on Patients without Covid-19. Engl J Med. 2020 - PubMed
-
- Masumi U., Renato M., Paul C.H. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Comprehens Cancer Netw J Natl Compr Canc Netw. 2020:1–4. - PubMed
LinkOut - more resources
Full Text Sources
